Biotech Giants Clash Over mRNA Vaccine Patents
German biotech firm CureVac has filed a lawsuit against Moderna in Delaware, alleging patent infringement of its mRNA technology in Moderna's COVID-19 vaccine, Spikevax. The case is among several patent disputes in the biotech sector as companies vie for royalties from successful COVID-19 vaccines.
CureVac, a German biotech company, has initiated legal proceedings against Moderna in Delaware federal court, asserting that Moderna's COVID-19 vaccine, Spikevax, infringes on CureVac's patents concerning messenger RNA (mRNA) technology.
The lawsuit claims Moderna improperly utilized CureVac's stabilization technology for fragile mRNA in its vaccines and seeks royalties from Spikevax sales. CureVac's move follows BioNTech's acquisition and subsequent separate patent lawsuit against Moderna earlier this year.
This legal action is part of a broader wave of high-stakes patent litigation in the biotech industry as companies aim for compensation for technologies used in lucrative COVID-19 vaccines. The ongoing legal battles include a suit Moderna filed against Pfizer and BioNTech in 2022.
(With inputs from agencies.)
ALSO READ
Jury Rules Against Elon Musk in OpenAI Lawsuit: Timing and Trust on Trial
Trump Withdraws $10 Billion IRS Lawsuit Amidst Controversial Fund Proposal
Social Media Giants Settle Landmark Mental Health Lawsuit with Schools
High-Stakes Lawsuit: Elon Musk Takes OpenAI to Court Over Alleged Breach of Charitable Trust
Google News